

Peter A Merkel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2052517/publications.pdf>

Version: 2024-02-01

312
papers

30,308
citations

7672

79
h-index

6349

163
g-index

327
all docs

327
docs citations

327
times ranked

20196
citing authors

#	ARTICLE	IF	CITATIONS
1	Core Set of Domains for Outcome Measures in Behçet's Syndrome. <i>Arthritis Care and Research</i> , 2022, 74, 691-699.	1.5	21
2	Reply. <i>Arthritis and Rheumatology</i> , 2022, 74, 545-546.	2.9	0
3	Hypothyroidism in vasculitis. <i>Rheumatology</i> , 2022, 61, 2942-2950.	0.9	2
4	Serum Biomarkers of Disease Activity in Longitudinal Assessment of Patients with ANCA-associated Vasculitis. <i>ACR Open Rheumatology</i> , 2022, 4, 168-176.	0.9	6
5	Patient Perceptions and Preferences Regarding Telemedicine for Autoimmune Rheumatic Diseases Care During the COVID-19 Pandemic. <i>Arthritis Care and Research</i> , 2022, 74, 1049-1057.	1.5	10
6	Use of 18F-fluorodeoxyglucose positron emission tomography to standardize clinical trial recruitment in Takayasu's arteritis. <i>Rheumatology</i> , 2022, 61, 4047-4055.	0.9	10
7	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 386-392.	2.9	50
8	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 309-314.	0.5	157
9	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 393-399.	2.9	71
10	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 321-326.	0.5	112
11	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. <i>Arthritis and Rheumatology</i> , 2022, 74, 400-406.	2.9	62
12	2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 315-320.	0.5	145
13	Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. <i>Arthritis Care and Research</i> , 2022, 74, 733-740.	1.5	16
14	Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review. <i>BMJ Open</i> , 2022, 12, e050507.	0.8	11
15	The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. <i>BMJ</i> , The, 2022, 376, e064604.	3.0	42
16	Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review. <i>Rheumatology</i> , 2022, 61, 4603-4618.	0.9	7
17	Response to: Correspondence on "2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis" by Joanna C Robson et al and "2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis" by Ravi Suppiah et al. <i>Annals of the Rheumatic Diseases</i> , 2022, , annrheumdis-2022-222362.	0.5	12
18	Obinutuzumab as treatment for ANCA-associated vasculitis. <i>Rheumatology</i> , 2022, 61, 3814-3817.	0.9	11

#	ARTICLE	IF	CITATIONS
19	The glucocorticoid toxicity index: Measuring change in glucocorticoid toxicity over time. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152010.	1.6	32
20	FC057: Incidence of Infections in the Avacopan Group Versus Prednisone Group in Anca-Associated Vasculitis, Results from the Phase 3 Advocate Study. <i>Nephrology Dialysis Transplantation</i> , 2022, 37, .	0.4	0
21	An international Delphi exercise to identify items of importance for measuring response to treatment in ANCA-associated vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 55, 152021.	1.6	2
22	Self-Reported Data and Physician-Reported Data in Patients With Eosinophilic Granulomatosis With Polyangiitis: Comparative Analysis. <i>Interactive Journal of Medical Research</i> , 2022, 11, e27273.	0.6	2
23	Neutrophil activation in patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis and large-vessel vasculitis. <i>Arthritis Research and Therapy</i> , 2022, 24, .	1.6	12
24	Targeted Program in an Academic Rheumatology Practice to Improve Compliance With Opioid Prescribing Guidelines for the Treatment of Chronic Pain. <i>Arthritis Care and Research</i> , 2021, 73, 1425-1429.	1.5	4
25	Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in <i>ADA2</i> . <i>Arthritis and Rheumatology</i> , 2021, 73, 512-519.	2.9	34
26	Considerations for a combined index for limited cutaneous systemic sclerosis to support drug development and improve outcomes. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 66-76.	1.0	12
27	Concerns, Healthcare Use, and Treatment Interruptions in Patients With Common Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. <i>Journal of Rheumatology</i> , 2021, 48, 603-607.	1.0	56
28	Clinical course of 602 patients with Takayasu's arteritis: comparison between Childhood-onset versus adult onset disease. <i>Rheumatology</i> , 2021, 60, 2246-2255.	0.9	44
29	Effects of the COVID-19 Pandemic on Patients Living With Vasculitis. <i>ACR Open Rheumatology</i> , 2021, 3, 17-24.	0.9	10
30	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	2.6	26
31	Response to: "Correspondence on Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis" by Parikh et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2020-219329.	0.5	1
32	Avacopan for the Treatment of ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2021, 384, 599-609.	13.9	461
33	Multifocal neutrophilic meningoencephalitis: a novel disorder responsive to anakinra. <i>Journal of Neurology</i> , 2021, 268, 2995-2999.	1.8	1
34	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1089-1089.	2.9	0
35	Pulmonary involvement in primary systemic vasculitides. <i>Rheumatology</i> , 2021, 61, 319-330.	0.9	16
36	Patient-Powered Research Networks of the Autoimmune Research Collaborative: Rationale, Capacity, and Future Directions. <i>Patient</i> , 2021, 14, 699-710.	1.1	13

#	ARTICLE	IF	CITATIONS
37	P158 Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic-related digital vasculopathy: a systematic literature review. <i>Rheumatology</i> , 2021, 60, .	0.9	0
38	Diagnostic delays in vasculitis and factors associated with time to diagnosis. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 184.	1.2	20
39	Clinical Manifestations and Long-Term Outcomes of Eosinophilic Granulomatosis With Polyangiitis in North America. <i>ACR Open Rheumatology</i> , 2021, 3, 404-412.	0.9	21
40	FC 032 THE EFFECT OF AVACOPAN, A COMPLEMENT C5A RECEPTOR INHIBITOR, ON KIDNEY FUNCTION IN PATIENTS WITH ANCA-ASSOCIATED VASCULITIS WITH RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.4	0
41	Social Distancing, Health Care Disruptions, Telemedicine Use, and Treatment Interruption During the COVID-19 Pandemic in Patients With or Without Autoimmune Rheumatic Disease. <i>ACR Open Rheumatology</i> , 2021, 3, 381-389.	0.9	19
42	Developing a core set of outcome measure domains to study Raynaud's phenomenon and digital ulcers in systemic sclerosis: Report from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 640-643.	1.6	8
43	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis Care and Research</i> , 2021, 73, 1088-1105.	1.5	90
44	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1366-1383.	2.9	249
45	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1349-1365.	2.9	231
46	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis and Rheumatology</i> , 2021, 73, 1384-1393.	2.9	32
47	Dynamic Changes in the Nasal Microbiome Associated With Disease Activity in Patients With Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2021, 73, 1703-1712.	2.9	14
48	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Polyarteritis Nodosa. <i>Arthritis Care and Research</i> , 2021, 73, 1061-1070.	1.5	15
49	2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. <i>Arthritis Care and Research</i> , 2021, 73, 1071-1087.	1.5	61
50	Developing a composite outcome tool to measure response to treatment in ANCA-associated vasculitis: A mixed methods study from OMERACT 2020. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1134-1138.	1.6	4
51	Eosinophils in Health and Disease: A State-of-the-Art Review. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2694-2707.	1.4	103
52	Circulating autoreactive proteinase 3+ B cells and tolerance checkpoints in ANCA-associated vasculitis. <i>JCI Insight</i> , 2021, 6, .	2.3	7
53	Composite outcomes at OMERACT: Multi-outcome domains and composite outcome domains. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1370-1377.	1.6	3
54	Efficacy of leflunomide in the treatment of vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 114-118.	0.4	3

#	ARTICLE	IF	CITATIONS
55	Urinary soluble CD163 and monocyte chemoattractant protein-1 in the identification of subtle renal flare in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 283-291.	0.4	40
56	Effect of Treatment on Imaging, Clinical, and Serologic Assessments of Disease Activity in Large-vessel Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 99-107.	1.0	48
57	Derivation of an angiographically based classification system in Takayasu's arteritis: an observational study from India and North America. <i>Rheumatology</i> , 2020, 59, 1118-1127.	0.9	33
58	Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis. <i>Journal of Rheumatology</i> , 2020, 47, 1001-1010.	1.0	20
59	Patterns of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. <i>Arthritis Care and Research</i> , 2020, 72, 1615-1624.	1.5	77
60	Diagnostic Assessment Strategies and Disease Subsets in Giant Cell Arteritis: Data From an International Observational Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 667-676.	2.9	33
61	Outcome Measures in Large Vessel Vasculitis: Relationship Between Patient, Physician, Imaging, and Laboratory-Based Assessments. <i>Arthritis Care and Research</i> , 2020, 72, 1296-1304.	1.5	23
62	Assessment of skin disease in scleroderma: Practices and opinions of investigators studying scleroderma. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 167-171.	1.0	7
63	Adjunctive Treatment With Avacopan, an Oral C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>ACR Open Rheumatology</i> , 2020, 2, 662-671.	0.9	64
64	Use and reporting of outcome measures in randomized trials for anti-neutrophil cytoplasmic antibody-associated vasculitis: a systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1314-1325.	1.6	17
65	ANCA-associated vasculitis. <i>Nature Reviews Disease Primers</i> , 2020, 6, 71.	18.1	443
66	Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3 in ANCA-Associated Vasculitis. <i>Frontiers in Immunology</i> , 2020, 11, 2053.	2.2	12
67	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020, 21, 362.	0.7	14
68	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1741-1747.	2.9	31
69	Harnessing health plan enrollee data to boost membership in patient-powered research networks. <i>BMC Health Services Research</i> , 2020, 20, 462.	0.9	2
70	Long-Term Safety of Rituximab in Granulomatosis with Polyangiitis or Microscopic Polyangiitis. <i>Arthritis Care and Research</i> , 2020, 73, 1372-1378.	1.5	11
71	A novel approach to conducting clinical trials in the community setting: utilizing patient-driven platforms and social media to drive web-based patient recruitment. <i>BMC Medical Research Methodology</i> , 2020, 20, 58.	1.4	20
72	Performance of laser-derived imaging for assessing digital perfusion in clinical trials of systemic sclerosis-related digital vasculopathy: A systematic literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1114-1130.	1.6	11

#	ARTICLE	IF	CITATIONS
73	Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2020, 382, 622-631.	13.9	465
74	Clinical associations of renal involvement in ANCA-associated vasculitis. <i>Autoimmunity Reviews</i> , 2020, 19, 102495.	2.5	47
75	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. <i>Rheumatology</i> , 2020, 59, 487-494.	0.9	56
76	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. <i>Rheumatology</i> , 2020, 59, e1-e23.	0.9	128
77	Comment on: Derivation of an angiographically based classification system in Takayasu's arteritis: reply. <i>Rheumatology</i> , 2020, 59, 1184-1185.	0.9	1
78	Pulmonary Eosinophilic Granulomatosis with Polyangiitis Has IgG4 Plasma Cells and Immunoregulatory Features. <i>American Journal of Pathology</i> , 2020, 190, 1438-1448.	1.9	7
79	Patterns of clinical presentation in Takayasu's arteritis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 576-581.	1.6	25
80	Fc receptor-like 5 and anti-CD20 treatment response in granulomatosis with polyangiitis and microscopic polyangiitis. <i>JCI Insight</i> , 2020, 5, .	2.3	6
81	Evaluation of the Safety and Efficacy of Avacopan, a C5a Receptor Inhibitor, in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Treated Concomitantly With Rituximab or Cyclophosphamide/Azathioprine: Protocol for a Randomized, Double-Blind, Active-Controlled, Phase 3 Trial. <i>JMIR Research Protocols</i> , 2020, 9, e16664.	0.5	50
82	Clinical Characteristics of an Internet-Based Cohort of Patient-Reported Diagnosis of Granulomatosis With Polyangiitis and Microscopic Polyangiitis: Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e17231.	2.1	13
83	Identifying Clinical Risk Factors for Opioid Use Disorder using a Distributed Algorithm to Combine Real-World Data from a Large Clinical Data Research Network. <i>AMIA ... Annual Symposium proceedings</i> , 2020, 2020, 1220-1229.	0.2	1
84	Early development of new cardiovascular risk factors in the systemic vasculitides. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 126-134.	0.4	2
85	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.0	13
86	Arterial lesions in giant cell arteritis: A longitudinal study. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 707-713.	1.6	43
87	The association of serum interleukin-6 levels with clinical outcomes in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Journal of Autoimmunity</i> , 2019, 105, 102302.	3.0	24
88	Patient involvement in medical research: what patients and physicians learn from each other. <i>Orphanet Journal of Rare Diseases</i> , 2019, 14, 21.	1.2	29
89	Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Randomized Controlled Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 952-963.	2.9	82
90	Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2170-2177.	1.5	82

#	ARTICLE	IF	CITATIONS
91	MultiPLIER: A Transfer Learning Framework for Transcriptomics Reveals Systemic Features of Rare Disease. <i>Cell Systems</i> , 2019, 8, 380-394.e4.	2.9	92
92	Subglottic stenosis and endobronchial disease in granulomatosis with polyangiitis. <i>Rheumatology</i> , 2019, 58, 2203-2211.	0.9	37
93	Association of Pulmonary Hemorrhage, Positive Proteinase 3, and Urinary Red Blood Cell Casts With Venous Thromboembolism in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1888-1893.	2.9	25
94	Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1879-1887.	2.9	23
95	Data linkages between patient-powered research networks and health plans: a foundation for collaborative research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2019, 26, 594-602.	2.2	14
96	Update on Outcome Measure Development in Large-vessel Vasculitis: Report from OMERACT 2018. <i>Journal of Rheumatology</i> , 2019, 46, 1198-1201.	1.0	24
97	<p>Systemic vasculitis and patient-reported outcomes: how the assessment of patient preferences and perspectives could improve outcomes</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 37-42.	0.7	9
98	Feasibility and Construct Validation of the Patient Reported Outcomes Measurement Information System in Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2019, 46, 928-934.	1.0	6
99	Peripheral neuropathy in antineutrophil cytoplasmic antibody-associated vasculitides. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2019, 6, .	3.1	34
100	Ascending Aortic Aneurysm Secondary to Isolated Noninfectious Ascending Aortitis. <i>Journal of Clinical Rheumatology</i> , 2019, 25, 186-194.	0.5	4
101	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
102	Updating OMERACT Core Set of Domains for ANCA-associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability, and Health. <i>Journal of Rheumatology</i> , 2019, 46, 1415-1420.	1.0	7
103	Serum cytokine and chemokine levels in patients with eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, or eosinophilic asthma. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 117, 40-44.	0.4	7
104	Patients' experiences with Behçet's syndrome: structured interviews among patients with different types of organ involvement. <i>Clinical and Experimental Rheumatology</i> , 2019, 37 Suppl 121, 28-34.	0.4	4
105	Evaluation of damage in giant cell arteritis. <i>Rheumatology</i> , 2018, 57, 322-328.	0.9	28
106	Comparison of magnetic resonance angiography and ¹⁸ F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1165-1171.	0.5	101
107	Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 1114-1121.	2.9	49
108	Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. <i>Rheumatology</i> , 2018, 57, 639-650.	0.9	20

#	ARTICLE	IF	CITATIONS
109	Cross-phenotype analysis of ImmunoChip data identifies <i>KDM4C</i> as a relevant locus for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 589-595.	0.5	27
110	The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 251-257.	2.2	50
111	Validation of the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212713.	0.5	38
112	¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography As an Imaging Biomarker in a Prospective, Longitudinal Cohort of Patients With Large Vessel Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 439-449.	2.9	241
113	Patient perceptions of glucocorticoids in anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Rheumatology International</i> , 2018, 38, 675-682.	1.5	40
114	Nomenclature of Cutaneous Vasculitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 171-184.	2.9	200
115	Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis. <i>Steroids</i> , 2018, 140, 159-166.	0.8	24
116	Serum periostin as a biomarker in eosinophilic granulomatosis with polyangiitis. <i>PLoS ONE</i> , 2018, 13, e0205768.	1.1	6
117	Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 17-34.	0.7	24
118	Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis. <i>Arthritis and Rheumatology</i> , 2018, 70, 2077-2086.	2.9	12
119	Characterisation of the nasal microbiota in granulomatosis with polyangiitis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1448-1453.	0.5	37
120	Metabolic pathways and immunometabolism in rare kidney diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, annrheumdis-2017-212935.	0.5	101
121	Impact of vasculitis on employment and income. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 58-64.	0.4	4
122	Health-related outcomes of importance to patients with Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 111, 51-57.	0.4	6
123	The association of vascular risk factors with visual loss in giant cell arteritis. <i>Rheumatology</i> , 2017, 56, kew397.	0.9	16
124	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 846-853.	2.9	131
125	A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 837-845.	2.9	271
126	Infections and the risk of incident giant cell arteritis: a population-based, case-control study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1031-1035.	0.5	51

#	ARTICLE	IF	CITATIONS
127	Analysis of the common genetic component of large-vessel vasculitides through a meta-ImmunoChip strategy. <i>Scientific Reports</i> , 2017, 7, 43953.	1.6	52
128	Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. <i>Trials</i> , 2017, 18, 112.	0.7	65
129	Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. <i>New England Journal of Medicine</i> , 2017, 376, 1921-1932.	13.9	682
130	Developing a Core Set of Outcome Measures for Behçet Disease: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1750-1753.	1.0	25
131	Reply. <i>Arthritis and Rheumatology</i> , 2017, 69, 1505-1506.	2.9	0
132	Are the 1990 American College of Rheumatology vasculitis classification criteria still valid?. <i>Rheumatology</i> , 2017, 56, 1154-1161.	0.9	89
133	Temporal Trends of Venous Thromboembolism Risk Before and After Diagnosis of Giant Cell Arteritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 176-184.	2.9	22
134	Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 1054-1066.	2.9	130
135	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , 2017, 100, 64-74.	2.6	78
136	Composition corporelle, fonction pulmonaire et perte progressive de masse osseuse chez lâ€™adulte souffrant de mucoviscidose. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2017, 84, 51-56.	0.0	0
137	Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis. <i>American Journal of Nephrology</i> , 2017, 46, 231-238.	1.4	15
138	Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1933-1937.	1.0	33
139	Assessment of Disease Activity in Large-vessel Vasculitis: Results of an International Delphi Exercise. <i>Journal of Rheumatology</i> , 2017, 44, 1928-1932.	1.0	22
140	The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica. <i>Journal of Rheumatology</i> , 2017, 44, 1515-1521.	1.0	33
141	Patient-reported outcomes in Takayasu's arteritis. <i>Presse Medicale</i> , 2017, 46, e225-e227.	0.8	4
142	Severe Infection in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1468-1475.	1.0	47
143	Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Rheumatology</i> , 2017, 56, 1962-1969.	0.9	48
144	Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. <i>RMD Open</i> , 2017, 3, e000449.	1.8	23

#	ARTICLE	IF	CITATIONS
145	Rate of Comorbidities in Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2017, 44, 84-90.	1.0	43
146	Variation in the Treatment of Children Hospitalized With Antineutrophil Cytoplasmic Antibody-associated Vasculitis in the US. <i>Arthritis Care and Research</i> , 2017, 69, 1377-1383.	1.5	15
147	The Pharmacogenomic Association of Fcγ ₃ Receptors and Cytochrome P450 Enzymes With Response to Rituximab or Cyclophosphamide Treatment in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 169-175.	2.9	21
148	Patient-Reported Outcomes in Glomerular Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 140-148.	2.2	24
149	Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis Care and Research</i> , 2017, 69, 1004-1010.	1.5	11
150	Association of Serum Calprotectin (S100A8/A9) Level With Disease Relapse in Proteinase 3-antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2017, 69, 185-193.	2.9	45
151	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 11-18.	1.0	321
152	Experience With Direct-to-Patient Recruitment for Enrollment Into a Clinical Trial in a Rare Disease: A Web-Based Study. <i>Journal of Medical Internet Research</i> , 2017, 19, e50.	2.1	24
153	OMERACT Endorsement of Patient-reported Outcome Instruments in Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2017, 44, 1529-1535.	1.0	25
154	Clinical course and outcomes of childhood-onset granulomatosis with polyangiitis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 202-208.	0.4	5
155	IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 103, 98-101.	0.4	3
156	The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. <i>Orphanet Journal of Rare Diseases</i> , 2016, 11, 66.	1.2	62
157	Trends in Long-term Outcomes Among Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis With Renal Disease. <i>Arthritis and Rheumatology</i> , 2016, 68, 1711-1720.	2.9	97
158	Using Mass Spectrometry to Quantify Rituximab and Perform Individualized Immunoglobulin Phenotyping in ANCA-Associated Vasculitis. <i>Analytical Chemistry</i> , 2016, 88, 6317-6325.	3.2	24
159	The Birmingham Vasculitis Activity Score as a Measure of Disease Activity in Patients with Giant Cell Arteritis. <i>Journal of Rheumatology</i> , 2016, 43, 1078-1084.	1.0	37
160	Effect of Macitentan on the Development of New Ischemic Digital Ulcers in Patients With Systemic Sclerosis. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1975.	3.8	95
161	Diffuse atrophic papules and plaques, intermittent abdominal pain, paresthesias, and cardiac abnormalities in a 55-year-old woman. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 1274-1277.	0.6	9
162	Myeloperoxidase-antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's): Distinct Patient Subsets. <i>Arthritis and Rheumatology</i> , 2016, 68, 2945-2952.	2.9	75

#	ARTICLE	IF	CITATIONS
163	Development and validation of case-finding algorithms for the identification of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis in large healthcare administrative databases. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1368-1374.	0.9	29
164	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	1.5	13
165	Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3. <i>Arthritis and Rheumatology</i> , 2016, 68, 1700-1710.	2.9	132
166	Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study. <i>Journal of Rheumatology</i> , 2016, 43, 1559-1565.	1.0	59
167	Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. <i>Journal of Rheumatology</i> , 2016, 43, 1553-1558.	1.0	38
168	Body composition, lung function, and prevalent and progressive bone deficits among adults with cystic fibrosis. <i>Joint Bone Spine</i> , 2016, 83, 207-211.	0.8	15
169	Using patient-reported outcomes and PROMIS in research and clinical applications: experiences from the PCORI pilot projects. <i>Quality of Life Research</i> , 2016, 25, 2109-2116.	1.5	51
170	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016, 46, 48-51.	0.8	31
171	Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1166-1169.	0.5	196
172	Vasculitis in patients with inflammatory bowel diseases: A study of 32 patients and systematic review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 475-482.	1.6	109
173	Severe Small-Vessel Vasculitis Temporally Associated With Administration of Ustekinumab. <i>Journal of Drugs in Dermatology</i> , 2016, 15, 359-62.	0.4	5
174	Mapping of the Outcome Measures in Rheumatology Core Set for Antineutrophil Cytoplasmic Antibody-associated Vasculitis to the International Classification of Function, Disability and Health. <i>Arthritis Care and Research</i> , 2015, 67, 255-263.	1.5	9
175	Adverse Events in Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2015, 67, 2457-2465.	2.9	12
176	Serum Biomarkers in Patients with Relapsing Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss). <i>PLoS ONE</i> , 2015, 10, e0121737.	1.1	35
177	Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 993-997.	0.5	100
178	Reliability, validity and responsiveness to change of the Saint George's Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 1369-1379.	0.9	21
179	Identification of Susceptibility Loci in <i>IL6</i> , <i>RPS9</i> , and <i>LILRB3</i> , and an Intergenic Locus on Chromosome 21q22 in Takayasu Arteritis in a Genome-Wide Association Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1361-1368.	2.9	79
180	Apremilast for Behçet's Syndrome: A Phase 2, Placebo-Controlled Study. <i>New England Journal of Medicine</i> , 2015, 372, 1510-1518.	13.9	204

#	ARTICLE	IF	CITATIONS
181	Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study. <i>Journal of Rheumatology</i> , 2015, 42, 1213-1217.	1.0	129
182	Neutrophil-Related Gene Expression and Low-Density Granulocytes Associated With Disease Activity and Response to Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 1922-1932.	2.9	116
183	Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
184	Cardiac Involvement in Granulomatosis with Polyangiitis. <i>Journal of Rheumatology</i> , 2015, 42, 1209-1212.	1.0	87
185	Brief Report: Defining the Nasal Transcriptome in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2015, 67, 2233-2239.	2.9	17
186	A Large-Scale Genetic Analysis Reveals a Strong Contribution of the HLA Class II Region to Giant Cell Arteritis Susceptibility. <i>American Journal of Human Genetics</i> , 2015, 96, 565-580.	2.6	144
187	Allosteric modulation of proteinase 3 activity by anti-neutrophil cytoplasmic antibodies in granulomatosis with polyangiitis. <i>Journal of Autoimmunity</i> , 2015, 59, 43-52.	3.0	6
188	Outcome measures for Takayasu's arteritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 32-37.	2.0	34
189	Current Status, Goals, and Research Agenda for Outcome Measures Development in Behçet Syndrome: Report from OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2436-2441.	1.0	18
190	Trends in bone mineral density in young adults with cystic fibrosis over a 15 year period. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 526-532.	0.3	36
191	Comparison of Treatment Response in Idiopathic and Connective Tissue Disease-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1111-1117.	2.5	67
192	Exploration, Development, and Validation of Patient-reported Outcomes in Antineutrophil Cytoplasmic Antibody-associated Vasculitis Using the OMERACT Process. <i>Journal of Rheumatology</i> , 2015, 42, 2204-2209.	1.0	22
193	Update on Outcome Measure Development for Large Vessel Vasculitis: Report from OMERACT 12. <i>Journal of Rheumatology</i> , 2015, 42, 2465-2469.	1.0	33
194	Rituximab Versus Cyclophosphamide for ANCA-Associated Vasculitis with Renal Involvement. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 976-985.	3.0	137
195	Value of commonly measured laboratory tests as biomarkers of disease activity and predictors of relapse in eosinophilic granulomatosis with polyangiitis. <i>Rheumatology</i> , 2015, 54, 1351-1359.	0.9	52
196	Peripheral CD5+ B Cells in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2015, 67, 535-544.	2.9	25
197	The informational needs of patients with ANCA-associated vasculitis—development of an informational needs questionnaire. <i>Rheumatology</i> , 2014, 53, 1414-1421.	0.9	20
198	Causal Attributions about Disease Onset and Relapse in Patients with Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 923-930.	1.0	15

#	ARTICLE	IF	CITATIONS
199	P10. Review of the expert panel methodology in the diagnostic and classification criteria for vasculitis study: a pilot study. <i>Rheumatology</i> , 2014, 53, i15-i16.	0.9	1
200	Updating the OMERACT Filter: Core Areas as a Basis for Defining Core Outcome Sets. <i>Journal of Rheumatology</i> , 2014, 41, 994-999.	1.0	20
201	Brief Report: The Value of a Patient Global Assessment of Disease Activity in Granulomatosis With Polyangiitis (Wegener's). <i>Arthritis and Rheumatology</i> , 2014, 66, 428-432.	2.9	28
202	Current Status of Outcome Measure Development in Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 593-598.	1.0	31
203	An open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1376-1379.	0.5	128
204	Outcome Measures Used in Clinical Trials for Behçet Syndrome: A Systematic Review. <i>Journal of Rheumatology</i> , 2014, 41, 599-612.	1.0	54
205	Patient-powered research networks: building capacity for conducting patient-centered clinical outcomes research. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2014, 21, 583-586.	2.2	61
206	Alcohol-induced vasculitis: Case report and commentary. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e42-e43.	0.6	5
207	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52
208	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. <i>Annals of Internal Medicine</i> , 2014, 161, 230.	2.0	2
209	Risk for Cardiovascular Disease Early and Late After a Diagnosis of Giant-Cell Arteritis. <i>Annals of Internal Medicine</i> , 2014, 160, 73-80.	2.0	133
210	Correlates and Responsiveness to Change of Measures of Skin and Musculoskeletal Disease in Early Diffuse Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2014, 66, 1731-1739.	1.5	26
211	Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 417-427.	13.9	611
212	ACR/EULAR-endorsed study to develop Diagnostic and Classification Criteria for Vasculitis (DCVAS). <i>Clinical and Experimental Nephrology</i> , 2013, 17, 619-621.	0.7	158
213	Identification of Multiple Genetic Susceptibility Loci in Takayasu Arteritis. <i>American Journal of Human Genetics</i> , 2013, 93, 298-305.	2.6	143
214	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. <i>Arthritis and Rheumatism</i> , 2013, 65, 2737-2747.	6.7	2,359
215	Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1003-1010.	0.5	183
216	Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1342-1350.	0.5	109

#	ARTICLE	IF	CITATIONS
217	L50. The future of international clinical trials in vasculitis. <i>Presse Medicale</i> , 2013, 42, 637-641.	0.8	2
218	Pregnancy Outcomes Among Patients With Vasculitis. <i>Arthritis Care and Research</i> , 2013, 65, 1370-1374.	1.5	44
219	Association of Granulomatosis With Polyangiitis (Wegener's) With <i>HLA-DPB1*04</i> and <i>SEMA6A</i> Gene Variants: Evidence From Genome-Wide Analysis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2457-2468.	6.7	138
220	Clinical image: Spinal gout presenting as acute low back pain. <i>Arthritis and Rheumatism</i> , 2013, 65, n/a-n/a.	6.7	6
221	New Features of Disease After Diagnosis in 6 Forms of Systemic Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 1905-1912.	1.0	40
222	Urinary Biomarkers in Relapsing Antineutrophil Cytoplasmic Antibody-associated Vasculitis. <i>Journal of Rheumatology</i> , 2013, 40, 674-683.	1.0	39
223	Readability and Suitability Assessment of Patient Education Materials in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 1702-1706.	1.5	46
224	Illness Perceptions and Fatigue in Systemic Vasculitis. <i>Arthritis Care and Research</i> , 2013, 65, 1835-1843.	1.5	51
225	Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1329-1334.	0.5	218
226	Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis—a meta-analysis. <i>Rheumatology</i> , 2012, 51, 100-109.	0.9	285
227	Association of Vascular Physical Examination Findings and Arteriographic Lesions in Large Vessel Vasculitis. <i>Journal of Rheumatology</i> , 2012, 39, 303-309.	1.0	51
228	Patterns and predictors of change in outcome measures in clinical trials in scleroderma: An individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3420-3429.	6.7	69
229	Meta-analysis of genetic polymorphisms in granulomatosis with polyangiitis (Wegener's) reveals shared susceptibility loci with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 3463-3471.	6.7	33
230	Circulating Angiopoietin-2 as a Biomarker in ANCA-Associated Vasculitis. <i>PLoS ONE</i> , 2012, 7, e30197.	1.1	16
231	Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2012, 64, 273-279.	1.5	49
232	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. <i>Arthritis Care and Research</i> , 2012, 64, 351-357.	1.5	49
233	Defining disease activity and damage in patients with small-vessel vasculitis. <i>Cleveland Clinic Journal of Medicine</i> , 2012, 79, S11-S15.	0.6	9
234	Systemic vasculitis—is it time to reclassify?. <i>Rheumatology</i> , 2011, 50, 643-645.	0.9	41

#	ARTICLE	IF	CITATIONS
235	Granulomatosis with polyangiitis (Wegener's): An alternative name for Wegener's granulomatosis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 704-704.	0.5	106
236	Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 32-38.	0.5	394
237	Relationship Between Markers of Platelet Activation and Inflammation with Disease Activity in Wegener's Granulomatosis. <i>Journal of Rheumatology</i> , 2011, 38, 1048-1054.	1.0	45
238	Measurement of damage in systemic vasculitis: a comparison of the Vasculitis Damage Index with the Combined Damage Assessment Index. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 80-85.	0.5	47
239	Antineutrophil Cytoplasmic Antibodies, Autoimmune Neutropenia, and Vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 424-433.	1.6	19
240	Plasma Exchange for Renal Vasculitis and Idiopathic Rapidly Progressive Glomerulonephritis: A Meta-analysis. <i>American Journal of Kidney Diseases</i> , 2011, 57, 566-574.	2.1	179
241	The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis. <i>Journal of Rheumatology</i> , 2011, 38, 1480-1486.	1.0	105
242	Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda. <i>Journal of Rheumatology</i> , 2011, 38, 1471-1479.	1.0	79
243	A woman with severe lupus nephritis and difficult to control diabetes mellitus. <i>Arthritis Care and Research</i> , 2011, 63, 623-629.	1.5	6
244	A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis. <i>Arthritis Care and Research</i> , 2011, 63, 588-596.	1.5	147
245	Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis Care and Research</i> , 2011, 63, 1055-1061.	1.5	63
246	Ovarian reserve diminished by oral cyclophosphamide therapy for granulomatosis with polyangiitis (Wegener's). <i>Arthritis Care and Research</i> , 2011, 63, 1777-1781.	1.5	60
247	Granulomatosis with Polyangiitis (Wegener's): An alternative name for Wegener's Granulomatosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 863-864.	6.7	244
248	Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): Long-term followup of a multicenter longitudinal cohort. <i>Arthritis and Rheumatism</i> , 2011, 63, 2495-2503.	6.7	58
249	Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Arthritis and Rheumatism</i> , 2011, 63, 3988-3997.	6.7	59
250	IgA and IgG antineutrophil cytoplasmic antibody engagement of Fc receptor genetic variants influences granulomatosis with polyangiitis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20736-20741.	3.3	74
251	Granulomatosis with Polyangiitis (Wegener's). <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 587-588.	3.0	49
252	Assessment of disease activity and progression in Takayasu's arteritis. <i>Clinical and Experimental Rheumatology</i> , 2011, 29, S86-91.	0.4	56

#	ARTICLE	IF	CITATIONS
253	Genetics of vasculitis. <i>Current Opinion in Rheumatology</i> , 2010, 22, 157-163.	2.0	45
254	Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: A meta-analysis. <i>Arthritis Care and Research</i> , 2010, 62, 1166-1173.	1.5	200
255	Skin ulcers in a patient with Sjögren's syndrome. <i>Arthritis Care and Research</i> , 2010, 62, 1040-1046.	1.5	5
256	Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. <i>Arthritis Care and Research</i> , 2010, 62, 1639-1645.	1.5	86
257	Alpha ₁ -antitrypsin deficiency-related alleles Z and S and the risk of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2010, 62, 3760-3767.	6.7	87
258	Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. <i>New England Journal of Medicine</i> , 2010, 363, 221-232.	13.9	2,275
259	EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1744-1750.	0.5	139
260	Measures of Response in Clinical Trials of Systemic Sclerosis: The Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension Related to Systemic Sclerosis (EPOSS). <i>Journal of Rheumatology</i> , 2009, 36, 2356-2361.	1.0	43
261	Progress Towards a Core Set of Outcome Measures in Small-vessel Vasculitis. Report from OMERACT 9. <i>Journal of Rheumatology</i> , 2009, 36, 2362-2368.	1.0	35
262	Noninfectious Ascending Aortitis: Staying Ahead of the Curve. <i>Journal of Rheumatology</i> , 2009, 36, 2137-2140.	1.0	17
263	Recombinant human relaxin in the treatment of systemic sclerosis with diffuse cutaneous involvement: A randomized, double-blind, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2009, 60, 1102-1111.	6.7	137
264	Clinical research for rare disease: Opportunities, challenges, and solutions. <i>Molecular Genetics and Metabolism</i> , 2009, 96, 20-26.	0.5	320
265	Thromboembolic disease in vasculitis. <i>Current Opinion in Rheumatology</i> , 2009, 21, 41-46.	2.0	73
266	Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. <i>Arthritis and Rheumatism</i> , 2008, 58, 15-25.	6.7	1,918
267	Effects of glucocorticoids on weight change during the treatment of Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 746-753.	6.7	47
268	Validity, reliability, and feasibility of durometer measurements of scleroderma skin disease in a multicenter treatment trial. <i>Arthritis and Rheumatism</i> , 2008, 59, 699-705.	6.7	109
269	Case 31-2008. <i>New England Journal of Medicine</i> , 2008, 359, 1603-1614.	13.9	7
270	EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 605-617.	0.5	524

#	ARTICLE	IF	CITATIONS
271	Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis. <i>Annals of Internal Medicine</i> , 2007, 146, 621.	2.0	491
272	Antiproteinase 3 Antineutrophil Cytoplasmic Antibodies and Disease Activity in Wegener Granulomatosis. <i>Annals of Internal Medicine</i> , 2007, 147, 611.	2.0	234
273	Recombinant human anti- α -transforming growth factor β 1 antibody therapy in systemic sclerosis: A multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. <i>Arthritis and Rheumatism</i> , 2007, 56, 323-333.	6.7	415
274	Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. <i>Arthritis and Rheumatism</i> , 2007, 56, 2789-2797.	6.7	521
275	Nutrient Status of Adults with Cystic Fibrosis. <i>Journal of the American Dietetic Association</i> , 2007, 107, 2114-2119.	1.3	34
276	Outcome measures in systemic sclerosis: An update on instruments and current research. <i>Current Rheumatology Reports</i> , 2007, 9, 151-157.	2.1	57
277	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007, 34, 501-9.	1.0	45
278	Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations. <i>Journal of Rheumatology</i> , 2007, 34, 1027-31.	1.0	22
279	Systemic sclerosis - continuing progress in developing clinical measures of response. <i>Journal of Rheumatology</i> , 2007, 34, 1194-200.	1.0	64
280	The future of damage assessment in vasculitis. <i>Journal of Rheumatology</i> , 2007, 34, 1357-71.	1.0	33
281	The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event. <i>Journal of Rheumatology</i> , 2007, 34, 2446-50.	1.0	35
282	Brief Communication: High Incidence of Venous Thrombotic Events among Patients with Wegener Granulomatosis: The Wegener's Clinical Occurrence of Thrombosis (WeCLOT) Study. <i>Annals of Internal Medicine</i> , 2005, 142, 620.	2.0	277
283	A serum proteomic approach to gauging the state of remission in Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 2005, 52, 902-910.	6.7	43
284	Damage caused by Wegener's granulomatosis and its treatment: Prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET). <i>Arthritis and Rheumatism</i> , 2005, 52, 2168-2178.	6.7	171
285	Guide to Bone Health and Disease in Cystic Fibrosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 1888-1896.	1.8	388
286	Responsiveness of the SF-36 and the Health Assessment Questionnaire Disability Index in a systemic sclerosis clinical trial. <i>Journal of Rheumatology</i> , 2005, 32, 832-40.	1.0	107
287	Scleroderma--developing measures of response. <i>Journal of Rheumatology</i> , 2005, 32, 2477-80.	1.0	15
288	Current status of outcome measures in vasculitis: focus on Wegener's granulomatosis and microscopic polyangiitis. Report from OMERACT 7. <i>Journal of Rheumatology</i> , 2005, 32, 2488-95.	1.0	32

#	ARTICLE	IF	CITATIONS
289	Hearing Loss in Wegener's Granulomatosis. <i>Otology and Neurotology</i> , 2004, 25, 833-837.	0.7	50
290	Diagnostic imaging in Takayasu arteritis. <i>Current Opinion in Rheumatology</i> , 2004, 16, 31-37.	2.0	207
291	Domains of health-related quality of life important to patients with giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2003, 49, 819-825.	6.7	35
292	Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. <i>Journal of Rheumatology</i> , 2003, 30, 1630-47.	1.0	104
293	Evaluation and treatment of vasculitis in the critically ill patient. <i>Critical Care Clinics</i> , 2002, 18, 321-344.	1.0	9
294	A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. <i>Arthritis and Rheumatism</i> , 2002, 46, 1309-1318.	6.7	480
295	Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. <i>Arthritis and Rheumatism</i> , 2002, 46, 2410-2420.	6.7	272
296	A disease-specific activity index for Wegener's granulomatosis: Modification of the Birmingham Vasculitis Activity Score. <i>Arthritis and Rheumatism</i> , 2001, 44, 912-920.	6.7	400
297	Subacute bacterial endocarditis with positive cytoplasmic antineutrophil cytoplasmic antibodies and anti-proteinase 3 antibodies. <i>Arthritis and Rheumatism</i> , 2000, 43, 226-231.	6.7	165
298	Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: Prevalence among patients with high titers of antimyeloperoxidase antibodies. <i>Arthritis and Rheumatism</i> , 2000, 43, 405.	6.7	390
299	Evaluation of antineutrophil cytoplasmic antibody seroconversion induced by minocycline, sulfasalazine, or penicillamine. <i>Arthritis and Rheumatism</i> , 2000, 43, 2488-2492.	6.7	48
300	Alternating antineutrophil cytoplasmic antibody specificity: Drug-induced vasculitis in a patient with Wegener's granulomatosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 384-388.	6.7	43
301	Rheumatic disease and cystic fibrosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1563-1571.	6.7	34
302	Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: A multicenter, placebo-controlled, double-blind study. <i>Arthritis and Rheumatism</i> , 1998, 41, 670-677.	6.7	175
303	Drugs associated with vasculitis. <i>Current Opinion in Rheumatology</i> , 1998, 10, 45-50.	2.0	81
304	Measurement of functional status, self-assessment, and psychological well-being in scleroderma. <i>Current Opinion in Rheumatology</i> , 1998, 10, 589-594.	2.0	24
305	Prevalence of Antineutrophil Cytoplasmic Antibodies in a Large Inception Cohort of Patients with Connective Tissue Disease. <i>Annals of Internal Medicine</i> , 1997, 126, 866.	2.0	176
306	Heterotopic ossification in the setting of neuromuscular blockade. <i>Arthritis and Rheumatism</i> , 1997, 40, 1619-1627.	6.7	35

#	ARTICLE	IF	CITATIONS
307	The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. <i>American Journal of Medicine</i> , 1996, 101, 576-583.	0.6	158
308	Cocaine-associated cerebral vasculitis. <i>Seminars in Arthritis and Rheumatism</i> , 1995, 25, 172-183.	1.6	110
309	Evaluation of a simple office-based strategy for increasing influenza vaccine administration and the effect of differing reimbursement plans on the patient acceptance rate. <i>Journal of General Internal Medicine</i> , 1994, 9, 679-683.	1.3	35
310	Correction of Hyperinsulinemia by Glyburide Treatment in Nondiabetic Patients with Thalassemia Major. <i>Pediatric Research</i> , 1993, 33, 497-500.	1.1	13
311	Insulin Resistance and Hyperinsulinemia in Patients with Thalassemia Major Treated by Hypertransfusion. <i>New England Journal of Medicine</i> , 1988, 318, 809-814.	13.9	214
312	Re-Appraisal of the 1990 American College of Rheumatology Classification Criteria for Systemic Vasculitis: Analysis of Data from the Diagnostic and Classification Criteria in Vasculitis Study. <i>Rheumatology</i> , 0, , .	0.9	0